Drug Development

Evotec signs up for a 5-year discovery deal with Bayer focused on chronic kidney disease

Four years after Evotec first signed on to collaborate with Bayer on new therapies for endometriosis, the partners have decided to add a new discovery effort focused on chronic kidney disease.

Cord Dohrmann, Evotec

Cord Dohrmann, Evotec

Under the agreement, investigators at both companies will get a chance to contribute targets to the research effort. Evotec gets a guarantee of at least 14 million euros over the 5-year stretch of the collaboration. And there’s a chance to earn another $300 million euros in milestones.

Bayer so far has picked up five programs in its endometriosis pact, four preclinical and one in human trials.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented:

“This research alliance will particularly target chronic kidney diseases, which are the leading cause of end-stage renal disease. Currently, patients with end-stage renal disease face dialysis or kidney transplantation as the only available treatment options. There are no effective treatments that can significantly slow or reverse disease progression. We are very proud and excited to expand our efforts in kidney diseases together with Bayer in this area of enormous unmet medical need.”


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017